Compare Intuitive Surgical, Inc. (ISRG) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuitive Surgical, Inc. vs Twist Bioscience Corp — how do they compare? Intuitive Surgical, Inc. trades at $424.06 (market cap $146.76B), while Twist Bioscience Corp trades at $165.44 (market cap $10.08B). The key difference: Intuitive Surgical, Inc. is far larger — about 14.6× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Intuitive Surgical, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Intuitive Surgical, Inc. for 84 Days and Twist Bioscience Corp for 27 Days on average.
| ISRG | TWST | |
|---|---|---|
Market Cap | $146.76B | $10.08B |
Volume | 2,529,814 | 4,229,037 |
Sector | Health | Health |
52-Week High | $592.85 | $205.00 |
52-Week Low | $332.02 | $25.45 |
Typical Hold Time | 84 Days | 27 Days |
Enterprise Value | $141.54B | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuitive Surgical (ISRG) trades at $414.52, up 2.41% today, with strong bullish technical signals from moving averages. The company demonstrates robust fundamentals with revenue growth from $6.2B in 2022 to $10.1B in 2025 and net income margin expanding to 28.45%. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.80 surpassing the $2.48 forecast.
ISRG maintains a dominant position in robotic surgery with expanding international growth, though valuation multiples remain elevated with a P/E of 47.64. Analyst consensus is strongly bullish with a $480.78 price target representing 16% upside potential. Key risks include competitive pressures and international market volatility, particularly in China.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
